X 1. Full ownership of Adderall IR $335 Million X 2. In house marketing and distribution: Kirkov X 3. Generic OxyContin- FIRST TO FILE Aug 17, 2023 $720 Million —4. Full ownership of Adderall XR $ 1.56 Billion —5. Generic Concerta- $1.2 BILLION —6. Generic Vyvanse- $5.3 BILLION —7. Vigabatrin —8. Dopamine Agonist (probably Requip XL or Mirapex ER). $12 Million —9. Patented Unique ADF (w/o naltrexone)-- NDA —10. Mikah ANDA —11. Undisclosed —12. Antimetabolite ANDA- Methotrexate -$600 Million —13. Undisclosed Antimetabolite ANDA- $42 Million —14. Prasco/Burel Adderall agreement —15. Dexcel partnership approval by Israeli health for European distribution